Literature DB >> 22424402

Controversies in HIV cure research.

Rowena Johnston1, Françoise Barré-Sinoussi.   

Abstract

BACKGROUND: Antiretroviral therapy significantly reduces HIV viral burden and prolongs life, but does not cure HIV infection. The major scientific barrier to a cure is thought to be the persistence of the virus in cellular and/or anatomical reservoirs. DISCUSSION: Most efforts to date, including pharmaco, immuno or gene therapy, have failed to cure patients, with the notable exception of a stem cell transplant recipient commonly known as the Berlin patient. This case has revived interest in the potential to cure HIV infection and has highlighted the need to resolve critical questions in the basic, pre-clinical and clinical research spheres as they pertain specifically to efforts to eradicate HIV from the body of an infected person (a sterilizing cure) or at least render the need for lifelong antiretroviral therapy obsolete (functional cure). This paper describes ongoing debates in each of these research spheres as they were presented and discussed at a satellite session that took place at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Rome in July 2011.
SUMMARY: The resolution of these debates may have important implications for the search for a cure, the most efficient ways to identify and test promising interventions, and ultimately the availability of such a cure to diverse groups of HIV patients around the world.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22424402      PMCID: PMC3334674          DOI: 10.1186/1758-2652-15-16

Source DB:  PubMed          Journal:  J Int AIDS Soc        ISSN: 1758-2652            Impact factor:   5.396


  37 in total

1.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

Authors:  Ganesh Suntharalingam; Meghan R Perry; Stephen Ward; Stephen J Brett; Andrew Castello-Cortes; Michael D Brunner; Nicki Panoskaltsis
Journal:  N Engl J Med       Date:  2006-08-14       Impact factor: 91.245

2.  Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.

Authors:  R Liu; W A Paxton; S Choe; D Ceradini; S R Martin; R Horuk; M E MacDonald; H Stuhlmann; R A Koup; N R Landau
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

3.  HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression.

Authors:  R T Davey; N Bhat; C Yoder; T W Chun; J A Metcalf; R Dewar; V Natarajan; R A Lempicki; J W Adelsberger; K D Miller; J A Kovacs; M A Polis; R E Walker; J Falloon; H Masur; D Gee; M Baseler; D S Dimitrov; A S Fauci; H C Lane
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

4.  Fidelity of HIV-1 reverse transcriptase.

Authors:  B D Preston; B J Poiesz; L A Loeb
Journal:  Science       Date:  1988-11-25       Impact factor: 47.728

5.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

6.  Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells.

Authors:  Justin R Bailey; Ahmad R Sedaghat; Tara Kieffer; Timothy Brennan; Patricia K Lee; Megan Wind-Rotolo; Christine M Haggerty; Ashrit R Kamireddi; Yi Liu; Jessica Lee; Deborah Persaud; Joel E Gallant; Joseph Cofrancesco; Thomas C Quinn; Claus O Wilke; Stuart C Ray; Janet D Siliciano; Richard E Nettles; Robert F Siliciano
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

7.  Time to hit HIV, early and hard.

Authors:  D D Ho
Journal:  N Engl J Med       Date:  1995-08-17       Impact factor: 91.245

8.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

Authors:  D Finzi; M Hermankova; T Pierson; L M Carruth; C Buck; R E Chaisson; T C Quinn; K Chadwick; J Margolick; R Brookmeyer; J Gallant; M Markowitz; D D Ho; D D Richman; R F Siliciano
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

Review 9.  No acquisition: a new ambition for HIV vaccine development?

Authors:  Samir K Lakhashe; Guido Silvestri; Ruth M Ruprecht
Journal:  Curr Opin Virol       Date:  2011-10       Impact factor: 7.090

10.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Authors:  J K Wong; M Hezareh; H F Günthard; D V Havlir; C C Ignacio; C A Spina; D D Richman
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

View more
  11 in total

1.  Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands.

Authors:  Mihai V Putz; Nicoleta A Dudaș; Adriana Isvoran
Journal:  Int J Mol Sci       Date:  2015-08-18       Impact factor: 5.923

2.  Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses.

Authors:  Daniel A Donahue; Sophie M Bastarache; Richard D Sloan; Mark A Wainberg
Journal:  J Virol       Date:  2013-06-26       Impact factor: 5.103

3.  Inequality and ethics in paediatric HIV remission research: From Mississippi to South Africa and back.

Authors:  Johanna T Crane; Theresa M Rossouw
Journal:  Glob Public Health       Date:  2016-07-25

4.  A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model.

Authors:  Iart Luca Shytaj; Sandro Norelli; Barbara Chirullo; Alessandro Della Corte; Matt Collins; Jake Yalley-Ogunro; Jack Greenhouse; Nunzio Iraci; Edward P Acosta; Maria Letizia Barreca; Mark G Lewis; Andrea Savarino
Journal:  PLoS Pathog       Date:  2012-06-21       Impact factor: 6.823

5.  Residual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolution.

Authors:  Robert C Kauffman; Andradi Villalobos; Joanne H Bowen; Lourdes Adamson; Raymond F Schinazi
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

6.  Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART.

Authors:  Maria C Puertas; Marc Noguera-Julian; Marta Massanella; Christian Pou; Maria J Buzon; Bonaventura Clotet; Mario Stevenson; Roger Paredes; Julià Blanco; Javier Martinez-Picado
Journal:  Retrovirology       Date:  2016-08-02       Impact factor: 4.602

7.  Recruitment and ethical considerations in HIV cure trials requiring treatment interruption.

Authors:  Michael P Arnold; David Evans; Nelson Vergel
Journal:  J Virus Erad       Date:  2015-01-01

8.  Patterns of patient and healthcare provider viewpoints regarding participation in HIV cure-related clinical trials. Findings from a multicentre French survey using Q methodology (ANRS-APSEC).

Authors:  Christel Protière; Bruno Spire; Marion Mora; Isabelle Poizot-Martin; Marie Préau; Marjolaine Doumergue; Philippe Morlat; David Zucman; Cécile Goujard; François Raffi; Olivier Lambotte; Marie Suzan-Monti
Journal:  PLoS One       Date:  2017-11-02       Impact factor: 3.240

9.  Differences in HIV cure clinical trial preferences of French people living with HIV and physicians in the ANRS-APSEC study: a discrete choice experiment.

Authors:  Christel Protiere; Michael Arnold; Marion Fiorentino; Lisa Fressard; Jean D Lelièvre; Mohamed Mimi; François Raffi; Marion Mora; Laurence Meyer; Luis Sagaon-Teyssier; David Zucman; Marie Préau; Olivier Lambotte; Bruno Spire; Marie Suzan-Monti
Journal:  J Int AIDS Soc       Date:  2020-02       Impact factor: 5.396

10.  Synergies, tensions and challenges in HIV prevention, treatment and cure research: exploratory conversations with HIV experts in South Africa.

Authors:  Keymanthri Moodley; Theresa Rossouw; Ciara Staunton; Christopher J Colvin
Journal:  BMC Med Ethics       Date:  2016-04-30       Impact factor: 2.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.